**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Isabel Carvajal Juarez, Instituto Nacional de Cardiologia Ignacio Chavez, and UMAE Hospital de Cardiologia CMN SXXI IMSS,  Mexico City, Mexico.

**Main Body of the Abstract**
Background: In January 2021, the AMILO-LATAM research group was created to study the current prevalence of transthyretin cardiac amyloidosis (ATTR‐CA) in Latin America (LA), the degree of knowledge, its diagnosis and management among physicians, and promote registries and guidelines based on evidence and regional needs.
Methods: In the first two surveys, (n=488), we identified gaps in LA doctors' knowledge about the disease, its diagnosis and treatment, the poor use of non-invasive imaging methods, and the need for technological infrastructure. We created a work plan to improve knowledge, resource use, and diagnosis conditions.
In three years, we participated as speakers at more than 40 international conferences, presented five posters, and published four publications. In collaboration with ASNC, we held two free webinars (606 attendees from more than 35 countries). We created a Latin American Network of Nuclear Medicine Services to diagnose ATTR-CA in 113 centers in 18 LA countries. We carried out the same initial survey as a follow-up almost three years later. The information was automatically entered into a spreadsheet.
Results: We observed a significant improvement in knowledge about ATTR-CA, better identification of the red flags, and mayor correct use of imaging methods for non-invasive diagnosis.
Conclusion: We worked with educational programs, webinars, congress participation, and other measures to increase clinical awareness, which had a favorable impact on reducing the knowledge gap on ATTR-CA in LA. The red flags are clearer, and more PYP studies are requested, favoring the timely diagnosis of the disease.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Isabel Carvajal Juarez, Instituto Nacional de Cardiologia Ignacio Chavez, and UMAE Hospital de Cardiologia CMN SXXI IMSS,  Mexico City, Mexico.

**Main Body of the Abstract**
**Background:** In January 2021, the AMILO-LATAM research group was created to study the current prevalence of transthyretin cardiac amyloidosis (ATTR‐CA) in Latin America (LA), the degree of knowledge, its diagnosis and management among physicians, and promote registries and guidelines based on evidence and regional needs.
**Methods:** In the first two surveys, (n=488), we identified gaps in LA doctors' knowledge about the disease, its diagnosis and treatment, the poor use of non-invasive imaging methods, and the need for technological infrastructure. We created a work plan to improve knowledge, resource use, and diagnosis conditions.
In three years, we participated as speakers at more than 40 international conferences, presented five posters, and published four publications. In collaboration with ASNC, we held two free webinars (606 attendees from more than 35 countries). We created a Latin American Network of Nuclear Medicine Services to diagnose ATTR-CA in 113 centers in 18 LA countries. We carried out the same initial survey as a follow-up almost three years later. The information was automatically entered into a spreadsheet.
**Results:** We observed a significant improvement in knowledge about ATTR-CA, better identification of the red flags, and mayor correct use of imaging methods for non-invasive diagnosis.
**Conclusion:** We worked with educational programs, webinars, congress participation, and other measures to increase clinical awareness, which had a favorable impact on reducing the knowledge gap on ATTR-CA in LA. The red flags are clearer, and more PYP studies are requested, favoring the timely diagnosis of the disease.



Awareness and diagnosis of transthyretin cardiac amyloidosis in Latin America. Three years follow-up of the AMILO-LATAM research group PB144 (#557)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.